Tianhong Li

R. Perez-soler, Y. Ling, Tianhong Li, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

Tianhong Li, Jianda Yuan, Weijie Ma, 2016, Journal of Hematology & Oncology.

Retraction: The Phosphatase Inhibitor Menadione (Vitamin K3) Protects Cells from EGFR Inhibition by Erlotinib and Cetuximab

R. Perez-soler, Y. Zou, Y. Ling, 2013, Clinical Cancer Research.

The Phosphatase Inhibitor Menadione (Vitamin K3) Protects Cells from EGFR Inhibition by Erlotinib and Cetuximab

Tianhong Li, R. Perez-soler, Y. Zou, 2011, Clinical Cancer Research.

Cancer Therapy : Preclinical The Phosphatase Inhibitor Menadione ( Vitamin K 3 ) Protects Cells from EGFR Inhibition by Erlotinib and Cetuximab

R. Perez-soler, Y. Zou, Y. Ling, 2011 .

Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors

K. Kelly, D. Gandara, J. Bomalaski, 2015, Clinical Cancer Research.

Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer

E. Collisson, F. Kaye, I. Yeh, 2019, Clinical Cancer Research.

Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non–Small Cell Lung Cancer

P. Stephens, A. Shaw, S. Ou, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

D. Gandara, K. Danenberg, P. Mack, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Inhibiting Ras signaling in the therapy of breast cancer.

J. Sparano, Tianhong Li, 2003, Clinical breast cancer.

Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors.

J. Chen, Tianhong Li, Jianda Yuan, 2020, Cancer treatment and research.

Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey.

J. Gregg, K. Yoneda, Tianhong Li, 2019, Translational lung cancer research.

Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform.

C. Bult, E. Liu, J. Riess, 2015, Clinical lung cancer.

Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives

N. Stollenwerk, Tianhong Li, C. Phan, 2023, Biomarker Research.

Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.

Tianhong Li, D. Gandara, H. Kung, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of INC280 plus erlotinib in patients with MET expressing adenocarcinoma of the lung.

L. Beckett, J. Riess, K. Kelly, 2015 .

Targeting HER2 genomic alterations in non-small cell lung cancer

Tianhong Li, Weijie Ma, R. Young, 2021 .

Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).

J. Rigas, R. Perez-soler, Tianhong Li, 2010, Lung cancer.

Squamous Cell Transformation of Primary Lung Adenocarcinoma in a Patient With EML4-ALK Fusion Variant 5 Refractory to ALK Inhibitors.

J. Gregg, K. Yoneda, M. Daly, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors

T. Clark, J. Gregg, P. Stephens, 2018, Journal of Hematology & Oncology.

Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report

P. Stephens, K. Yoneda, G. Frampton, 2017, Journal of Hematology & Oncology.

Skin toxicities associated with epidermal growth factor receptor inhibitors

R. Perez-soler, Tianhong Li, 2009, Targeted Oncology.

Cancer neoantigens as potential targets for immunotherapy

Tianhong Li, Weijie Ma, B. Pham, 2021, Clinical & experimental metastasis.

Patient selection in non-small cell lung cancer: Histologic versus molecular subtypes?

Tianhong Li, 2010, Journal of thoracic disease.

Large-Scale Screening and Molecular Characterization of EML4-ALK Fusion Variants in Archival Non–Small-Cell Lung Cancer Tumor Specimens Using Quantitative Reverse Transcription Polymerase Chain Reaction Assays

Tianhong Li, L. Beckett, D. Gandara, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer

D. Gandara, K. Danenberg, P. Danenberg, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC

K. Yoneda, Tianhong Li, C. Phan, 2021, Biomarker Research.

Emerging EML4-ALK Variant 5 as a Concurrent Resistance Mechanism to Osimertinib in a Patient With EGFR E19del/T790M NSCLC.

Yan Yan, G. Jiang, Tianhong Li, 2020, Clinical lung cancer.

Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non–small‐cell Lung Cancer

L. Beckett, D. Gandara, R. Perez-soler, 2017, Clinical lung cancer.

Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications.

J. Riess, K. Kelly, D. Gandara, 2014, Clinical Lung Cancer.

Serum amylase elevation is associated with adverse clinical outcomes in patients with coronavirus disease 2019

Wei Wang, Bixiang Zhang, Tianhong Li, 2021, Aging.

CTEN prolongs signaling by EGFR through reducing its ligand-induced degradation.

S. Lo, K. Carraway, Tianhong Li, 2013, Cancer research.

Increasing cure rates of solid tumors by immune checkpoint inhibitors

Tianhong Li, C. Pan, Wenru Song, 2023, Experimental Hematology & Oncology.

949 First-in-human study of the first acid pH-sensitive and recycling CTLA-4 antibody that preserves the immune tolerance checkpoint to avoid immunotherapy-related adverse events in cancer patients

K. Kelly, Yang Liu, P. Zheng, 2021, Journal for ImmunoTherapy of Cancer.

Durable clinical response to the multidisciplinary management of neurosurgery, radiation and chemoimmunotherapy in a patient with PD-L1/PD-L2/JAK2 (PDJ)-amplified, refractory triple-negative breast cancer

G. Harsh, Arya Ashok, Tianhong Li, 2021, Journal of the National Cancer Center.

Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide.

J. Sparano, P. Munster, S. Sebti, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ensartinib (X-396): what does it add for patients with ALK-rearranged NSCLC.

Tianhong Li, Weijie Ma, E. Tian, 2019, Chinese clinical oncology.

A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial

Tianhong Li, Sanjiv S. Agarwala, Scott D. Christensen, 2010, Investigational New Drugs.

Expression of selenium-binding protein 1 characterizes intestinal cell maturation and predicts survival for patients with colorectal cancer.

D. Arango, Wancai Yang, J. Mariadason, 2008, Molecular nutrition & food research.

晚期非小细胞肺癌治疗策略的演变：从2009放眼2012

R. Herbst, D. Gandara, P. Mack, 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012.

R. Herbst, D. Gandara, P. Mack, 2009, Clinical lung cancer.

Survival Trends of Metastatic Lung Cancer in California by Age at Diagnosis, Gender, Race/Ethnicity, and Histology, 1990-2014.

R. Cress, Tianhong Li, K. Pan, 2020, Clinical lung cancer.

The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients.

F. Cappuzzo, H. Sugimura, B. Wan, 2019, Translational lung cancer research.

Phase II study of the farnesyl transferase inhibitor tipifarnib plus fulvestrant in postmenopausal patients with hormone receptor-positive breast cancer: New York Cancer Consortium Trial P6205

J. Sparano, J. Wright, P. Christos, 2007 .

Labyrinthin Expression Is Associated with Poor Prognosis in Patients with Non-Small-Cell Lung Cancer

Tianhong Li, J. Radosevich, Weijie Ma, 2023, Cancers.

High integrin α3 expression is associated with poor prognosis in patients with non-small cell lung cancer

Tianhong Li, Tao Wang, Weijie Ma, 2020, Translational lung cancer research.

Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Who Previously Progressed on Erlotinib

M. Socinski, K. Kelly, D. Gandara, 2015, Clinical Cancer Research.

Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer.

S. Wachsmann-Hogiu, R. deVere White, Qiangqiang Liu, 2016, Biomaterials.

Discovery and characterization of a high-affinity and high-specificity peptide ligand LXY30 for in vivo targeting of α3 integrin-expressing human tumors

Kit S Lam, Tianhong Li, Ruiwu Liu, 2016, EJNMMI Research.

Intravenous immunoglobulin is safe and effective in controlling pre-existing paraneoplastic neuromuscular diseases in cancer patients treated with immune checkpoint inhibitors: two case reports and literature review

D. Richman, R. Maselli, Tianhong Li, 2023, Frontiers in Oncology.

Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer.

J. Riess, K. Kelly, D. Gandara, 2017, Clinical lung cancer.

Bioengineering Novel Chimeric microRNA-34a for Prodrug Cancer Therapy: High-Yield Expression and Purification, and Structural and Functional Characterization

K. Lam, P. Limbach, B. Addepalli, 2015, The Journal of Pharmacology and Experimental Therapeutics.

Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity.

L. Beckett, K. Kelly, D. Gandara, 2012, Clinical lung cancer.

Intercalated Erlotinib-Docetaxel Dosing Schedules Designed to Achieve Pharmacodynamic Separation: Results of a Phase I/II Trial

D. Gandara, P. Mack, A. Davies, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MA04.07 Comparative Clinical Outcomes for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutations and Common EGFR Mutations

N. Girard, S. Ou, L. Bazhenova, 2021 .

A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103)

E. Perez, W. Gradishar, G. Sledge, 2012, Breast Cancer Research and Treatment.

Phase II study to evaluate the efficacy and safety of bortezomib (PS-341) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC)

J. Rigas, R. Perez-soler, Tianhong Li, 2008 .

Thymidylate synthase (TS) gene expression in patients with ALK positive (+) non-small cell lung cancer (NSCLC): Implications for therapy.

L. Beckett, D. Gandara, K. Danenberg, 2012 .

Biomarkers for the Immune Checkpoint Inhibitors

Tianhong Li, Weijie Ma, Sixi Wei, 2020 .

Safety and clinical activity of target-preserving anti-CTLA-4 antibody ONC-392 as monotherapy in NSCLC patients who progressed on PD(L)1-targeted immunotherapy.

Yang Liu, J. Hamm, P. Zheng, 2023, Journal of Clinical Oncology.

PRESERVE-003: Phase 3, two-stage, randomized study of ONC-392 versus docetaxel in metastatic non-small cell lung cancers that progressed on PD-1/PD-L1 inhibitors.

M. Socinski, Yang Liu, P. Zheng, 2023, Journal of Clinical Oncology.

The JAX patient-derived xenograft program: A unique resource to advance genome-guided cancer medicine and therapeutic agent testing.

Jeffrey H. Chuang, C. Bult, J. George, 2014 .

CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect

S. Hu-Lieskovan, Yang Liu, P. Zheng, 2021, Signal Transduction and Targeted Therapy.

Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC

J. Riess, D. Gandara, C. Blakely, 2022, JTO Clinical and Research Reports.

Novel Chimeric microRNA-34 a for Prodrug Cancer Therapy : High-Yield Expression and Purification , and Structural and Functional Characterization s

K. Lam, P. Limbach, B. Addepalli, 2015 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Disulfide-crosslinked nanomicelles confer cancer-specific drug delivery and improve efficacy of paclitaxel in bladder cancer

R. deVere White, M. Dall’Era, Tianhong Li, 2016, Nanotechnology.

Intercalated Erlotinib-Docetaxel Dosing Schedules Designed to Achieve Pharmacodynamic Separation: Results of a Phase I/II Trial

D. Gandara, P. Mack, A. Davies, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Phosphatase Inhibitor Menadione (Vitamin K3) Protects Cells from EGFR Inhibition by Erlotinib and Cetuximab

R. Perez-soler, Y. Zou, Y. Ling, 2011, Clinical Cancer Research.

Dynamic evaluation of blood immune cells predictive of response to immune checkpoint inhibitors in NSCLC by multicolor spectrum flow cytometry

M. Jaimes, Siqi Long, B. McLaughlin, 2023, Frontiers in Immunology.

L. Beckett, D. Gandara, K. Danenberg, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Biomarker analysis of a phase II trial of cabozantinib and erlotinib in patients (pts) with EGFR-mutant NSCLC with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance: A California Cancer Consortium Phase II Trial (NCI 9303).

D. Gandara, P. Mack, S. Gadgeel, 2015 .

Phase II study of the AKT inhibitor MK-2206 plus erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who progressed on prior erlotinib: A California Cancer Consortium Phase II trial (NCI 8698).

M. Socinski, K. Kelly, D. Gandara, 2014 .

Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer.

D. Gandara, R. Perez-soler, P. Mack, 2010, Current drug targets.

Src activation decouples cell division orientation from cell geometry in mammalian cells.

A. Mogilner, Xiaobing Fu, Min Zhao, 2018, Biomaterials.

KRAS mutations (MTs) in non-small cell lung cancer (NSCLC) versus colorectal cancer (CRC): Implications for cetuximab therapy.

D. Gandara, K. Danenberg, P. Danenberg, 2010 .